Pfizer's partnership with Halodoc promises to solve an access issue and create better patient engagement

Breast cancer is the most prevalent form of cancer in Indonesia, with an incidence of roughly 18.6 cases per 100,000 people annually. Pfizer is an industry leader in innovative breast cancer treatments, although it is facing competition from Novartis and Eli Lilly. The cost of breast cancer drugs ex...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email Thank you!

Related Research

First FDA approval given for virtual reality-based therapy for chronic back pain treatment

News Commentary | November 25, 2021

The U.S. Food and Drug Administration's approval for AppliedVR's EaseVRx system is supported by results from a clinical study of 179 patients, where two‑thirds reported a 30% reduction in pain. A three‑month follow‑up continued to show sustained pain reduction. Beyond these outcomes, the use of ... Not part of subscription

Regulus Therapeutics

Company Profile | December 01, 2021

Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription

Pfizer partnering with Alex Therapeutics to develop nicotine-addiction DTx

News Commentary | February 08, 2022

Pfizer has partnered with Stockholm‑based DTx (digital therapeutics) maker Alex Therapeutics to deploy artificial intelligence (AI)‑based digital therapeutics. The Alex DTx platform combines cognitive‑based therapy and acceptance and commitment therapy with AI to offer personalized treatment plans. ... Not part of subscription